Ignite Creation Date:
2025-12-26 @ 2:40 PM
Ignite Modification Date:
2025-12-26 @ 2:40 PM
Study NCT ID:
NCT01533506
Status:
NO_LONGER_AVAILABLE
Last Update Posted:
2013-02-28
First Post:
2012-02-09
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Stiripentol in Dravet Syndrome
Sponsor:
Mayo Clinic
Organization:
Study Overview
Official Title:
Compassionate Use of Stiripentol in Intractable Epilepsy Due to Dravet Syndrome
Status:
NO_LONGER_AVAILABLE
Status Verified Date:
2013-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The patient has failed all other available agents and has intractable epilepsy due to Dravet Syndrome. Stiripentol is highly efficacious in Dravet Syndrome. The overall goals of therapy with Stiripentol are primarily to significantly reduce the frequency and severity of seizures.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: